Analysts Offer Insights on Healthcare Companies: Mesoblast Ltd (NASDAQ: MESO) and Pfizer (NYSE: PFE)

By Jason Carr

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Mesoblast Ltd (NASDAQ:MESO) and Pfizer (NYSE:PFE) with bullish sentiments.

Mesoblast Ltd (MESO)

Maxim Group analyst Jason McCarthy assigned a Buy rating to Mesoblast Ltd today and set a price target of $16. The company’s shares closed yesterday at $6.75.

McCarthy commented:

“Mesoblast announced that the company entered into a partnership in (600535.SS – in chronic heart failure (CHF) and MPC-25-IC in acute myocardial infarction (AMI). We are factoring the China market into our model for HF and raising our price target to $16, from $14.”

According to TipRanks.com, McCarthy is a 5-star analyst with an average return of 12.5% and a 43.2% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as SELLAS Life Sciences Group Inc, ContraVir Pharmaceuticals Inc, and Sonoma Pharmaceuticals Inc.

Currently, the analyst consensus on Mesoblast Ltd is a Strong Buy with an average price target of $18, a 166.7% upside from current levels. In a report released yesterday, Cantor Fitzgerald also reiterated a Buy rating on the stock with a $23 price target.

.

See today’s analyst top recommended stocks >>

Pfizer (PFE)

Cantor Fitzgerald analyst Louise Chen assigned a Buy rating to Pfizer today and set a price target of $45. The company’s shares closed yesterday at $37.65.

Chen noted:

“We think respectable earnings growth, driven by IH and eventually EH, pipeline advancements, and return of capital to PFE’s shareholders — above the industry average — are all underappreciated. Therefore, multiple expansion and upward earnings revisions should drive PFE shares higher, in our view. Valuation Summary We use a blend of DCF and multiples (EV/EBITDA) analysis to get to our 12-month price target of $45.”

According to TipRanks.com, Chen is ranked 0 out of 5 stars with an average return of -4.7% and a 42.3% success rate. Chen covers the Healthcare sector, focusing on stocks such as Melinta Therapeutics Inc, Aclaris Therapeutics Inc, and Paratek Pharmaceuticals.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Pfizer with a $42 average price target, implying an 11.6% upside from current levels. In a report issued on July 11, BMO Capital also maintained a Buy rating on the stock with a $42 price target.

.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.